Drug Profile
Research programme: CNS disorder therapeutics - Umecrine
Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Umecrine
- Class
- Mechanism of Action GABA A receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued CNS disorders
Most Recent Events
- 12 Sep 2023 Discontinued - Preclinical for CNS disorders in Sweden (unspecified route) (Umecrine pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in CNS-disorders in Sweden
- 27 Jul 2016 Preclinical trials in CNS disorders in Sweden (unspecified route)